HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAsafety guidance54% confidence

Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28

Source: MHRA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Rhodes Pharmaceuticals.

Regulatory Analysis

Cadila Pharmaceuticals Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of Mirtazapine 30mg Film-Coated Tablets distributed in Crescent Pharma Limited livery.

Supporting Context

Therapeutic area
Pain Management · Opioid
Sub-indication
Pain

Related signal: FDA Accepts Supplemental NDA for Dilaudid by Rhodes Pharmaceuticals

Source

View source document

Related Signal

Open signal — FDA Accepts Supplemental NDA for Dilaudid by Rhodes Pharmaceuticals
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.